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Introduction
Diabetes mellitus (DM) is characterized by hyperglycemia causing many complications such as hyperlipidemia, atherosclerosis and other cardiovascular diseases [1] . The most common lipid abnormalities in DM are hypertriglyceridemia and hypercholesterolemia [2] . Hypertriglyceridemia contributes significantly for insulin resistance and glucose intolerance [3] . An excess of LDL (low density lipoprotein) cholesterol also causes atherosclerosis, narrowing of coronary artery due to plaque buildup on artery walls and blood clots, further blocking the blood supply to myocardium (heart attack). Cardiac arrest may also result from coronary artery disease (CAD). Ninety percent of sudden deaths occur in patients with two or more major arteries narrowed by atherosclerosis [4] . Abnormal lipid and lipoprotein levels lead to the development of CAD in diabetic patients [5] . Several studies have shown the benefits of lowering lipid levels to satisfactory levels to prevent diabetic complications [6, 7] .
In spite of the available modern antilipidemic drugs like fibrates and statins, there is a continuous search for new drugs due to the side effects associated with these drugs. In recent years, natural products have gained popularity as therapeutic agents in treating many diseases including DM and associated dyslipidemia because of the minimal to no side effects. Accumulating studies suggest that plant derived products were known to possess anti-diabetic and antihyperlipidemic activities [8] . In this study, an attempt was made to identify the anti-hyperlipidemic activity of Mcy protein that was isolated from the fruits of Momordica cymbalaria and its effect on liver and kidney.
Materials and Methods

Plant material
Fruits of M. cymbalaria were collected [9, 10] and Mcy protein was purified from the aqueous extract of fruits of M. cymbalaria as previously described [10] . In the current study Mcy protein was used at a dose of 2.5mg/kg b.w. as standardized earlier [10] .
Experimental design
Male Wistar Albino rats aged 2-3 months and weighing 180-200 gm were used for the study. The animals were maintained in standard animal house conditions with ad libitum access to food and water under a 12-hour light dark cycle prior to treatment. DM was induced in overnight fasted rats by single intravenous injection of freshly prepared ice cold Streptozotocin (STZ) (50mg/kg body weight) in citrate buffer (pH 4.5) [10] . Diabetes was confirmed by measuring fasting blood glucose concentrations. The rats with blood glucose levels >250mg/dl were considered as diabetic and used for the experiment. Fasting blood was collected to determine glucose levels every week starting on day one before treatment. The rats of groups 2 and 4 were given Mcy protein through intraperitoneal injection for a period of 4 weeks while groups 1 and 3 were injected with acetate buffer alone. Group 5 rats were given glibenclamide, an oral hypoglycemic agent, as a control. The blood glucose levels and body weights were checked in all groups for 4 weeks. Fasting blood glucose levels were measured using glucose-oxidaseperoxide reactive strips (Accu-chek, Roche Diagnostics, GmbH, Germany) [11] . All the rats were sacrificed on the last day (30 th day) of treatment by asphyxiation followed by cervical dislocation and the blood (with or without anticoagulant) and tissues were collected for various biochemical estimations. The blood was centrifuged at 7000 rpm for 15 minutes and plasma and serum were collected. For biochemical studies, tissues were frozen and stored at -80°C until used. For histology studies, tissues were immediately fixed in formalin as described below.
Histology
Histology of the pancreas and liver tissues were performed following standard methods [12] . The pancreas and liver tissues were excised and fixed in 10% buffered formalin and used to prepare paraffin blocks. Five-micrometer thick sections were cut with microtome and the tissue sections were stained with hematoxylin and eosin. 
Biochemical analysis
All the analyses were done using Prans Asia semi-automated analyzer. Serum cholesterol and HDLcholesterol were estimated by CHOD-POD [13] method. Serum triglycerides levels were estimated by the method of GPO-POD [14] . The activities of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were measured by IFCC/UV-kinetic method [15] . Serum creatinine, total Bilirubin and blood urea were measured by Jaffe's method [16] , modified Jendrassik-Grof's method [17] and Ned-dye method [18] respectively. LDL-cholesterol and VLDL-cholesterol were calculated by using Friedwald formula [19] . Glycated hemoglobin (HbA 1c ) was measured following the method of Eross et al. [20] . Insulin levels were measured by modified method of Herbert et al [21] using insulin radioimmunoassay kit obtained from BARC, Mumbai, India.
Atherogenic index was calculated using the formula given below. Atherogenic index = Total cholesterol -HDL-cholesterol/HDL-cholesterol [22] .
Oral glucose tolerance test
Another batch of rats were treated in the same way as described above. At the end of the treatment, rats were used for oral glucose tolerance test after overnight fasting. Following 30 minutes of post extract and drug administration, all the animals were orally fed with 2g glucose (solution)/kg b.w. with forcefeeding gavage. Blood samples were collected from tail vein prior to the treatment (0 min) and then at 30, 60, 90, 120, and 150 minutes after glucose administration. The blood glucose levels were measured using glucose-oxidase-peroxidase reactive strips (Accu-chek, Roche Diagnostics, GmbH, Germany).
Statistical analysis
The data for various biochemical parameters were analyzed using Analysis of Variance (ANOVA) and the significance was calculated using student's t-test. All the results were expressed as mean±SEM and the group means were compared by Duncan's multiple range test (DMRT) using SPSS 11.5 computer software.
Results
To study the effect of Mcy protein on glycemic control, we measured the fasting blood glucose levels, glycated hemoglobin, oral glucose tolerance and plasma insulin levels. Figure  1 shows the beneficial effect of Mcy protein on fasting blood glucose (Fig. 1A) , glycated hemoglobin (Fig. 1B) , oral glucose tolerance (Fig. 1C ) and plasma insulin levels (Fig. 1D) . It is evident that Mcy protein is a potent anti-hyperglycemic agent and decreased the glucose levels in diabetic treated group from 300 mg/dl to 96.5mg/dl after 4 weeks of treatment. Diabetic group displayed higher levels of HbA 1c compared to normal group (13±0.72% vs. 7.53±0.95). Where as with Mcy protein treatment, HbA 1c levels were reduced to near normal(7.6±0.8%). We further verified whether the treatment improves oral glucose tolerance with Mcy treatment and Mcy protein treated animals showed significant improvement in oral glucose tolerance (69% fall in blood glucose at 150 min, Fig. 1C ). The anti diabetic effect (indicated by HbA 1c and blood glucose) of Mcy protein was much better than that of glibenclamide. In addition, we verified the plasma insulin levels and observed a significant decrease in plasma insulin levels (Fig. 1D ) of diabetic untreated rats when compared to normal rats. However, the Mcy treatment in diabetic rats increased the insulin levels to a normal range (from 8.7±0.05 µU/ml to 12.9±0.05 µU/ml). As expected glibenclamide treated group also showed significant increase in plasma insulin levels.
To study the therapeutic effects of Mcy protein on hyperglycemia induced dyslipidemia we measured the lipid levels in various tissues including serum. Figure 2 shows the beneficial effect of Mcy protein on lipid levels of serum ( Fig. 2A), kidney (Fig. 2B), liver (Fig.  2C ) and skeletal muscle (Fig. 2D ) of experimental animals. Diabetic untreated rats showed increased levels of serum and tissue triglycerides, total cholesterol, LDL-cholesterol and VLDL cholesterol. However, Mcy protein significantly reduced the serum triglycerides (from 87mg/dl to 64mg/dl), total cholesterol (from 126mg/dl to 101.6mg/dl), LDL-cholesterol (from 37.23mg/dl to 29mg/dl) and VLDL-cholesterol (from 26mg/dl to 12.7mg/dl) (p<0.05) levels to near normal. Additionally, HDL-cholesterol, good cholesterol levels were Marella et 
significantly increased in the Mcy treated rats (from 24.66mg/dl to 43mg/dl) after the treatment ( Fig. 2A) . Similar results were also observed in the lipid levels of the other tissues tested, kidney (Fig. 2B) , liver ( Fig. 2C ) and skeletal muscle (Fig. 2D) . Furthermore, Table 1 shows the atherogenic index for the normal and diabetic rats with or without Mcy treatment. The atherogenic index for diabetic control rats is significantly higher than that in the normal rats. Conversely, Mcy protein treatment significantly reduced the atherogenic index to near normal.
To study the protective effects of Mcy protein on liver and kidney, we assayed serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) enzymes. We further measured blood urea, creatinine and total bilirubin levels. Fig.  3 shows the activities of hepatic function marker enzymes (SGOT and SGPT, Fig. 3A ) and concentrations of metabolites (urea, creatinine and total bilirubin, Fig. 3B-D) the markers of renal and hepatic functions. The activities of SGOT and SGPT were significantly decreased to near normal (from 41.5 IU/L to 35.3 IU/L and from 43.16 IU/L to 36 IU/L respectively) after the treatment with Mcy. Mcy protein also reduced the levels of creatinine (from 2.1 mg/dl to 0.9 mg/dl), bilirubin (from 1.7 mg/dl to 1.1 mg/dl) and urea (from 75.3 mg/dl to 64 mg/ dl) in diabetic treated rats to near normal values [ Fig. 3 ]. Glibenclamide treated diabetic rats also showed significant decrease in the activities of SGOT, SGPT and levels of urea, creatinine and total bilirubin. Figure 4 shows the histology of pancreas of normal (A), normal treated (B), diabetic control (C) and diabetic rats treated with Mcy protein (D). Control rats showed a normal lobular architecture of the pancreas with abundant islets of langerhans interspersed among the pancreatic exocrine acini. The islets appeared lightly stained than the surrounding acinar cells, with intact interlobular connective tissue and interlobular duct. The pancreatic sections of the diabetic group showed marked morphological changes and revealed changes in microanatomical features like congestion and β cell degranulation of the islets. Destruction of islet 
Discussion
DM characterized by hyperlipidemia may be due to the impaired actions of lipolytic hormones on the fat depots. Diabetic complications can be prevented by administration of traditional therapeutic principles [23] . Administration of Mcy protein normalized the levels of glucose, lipids, bilirubin, urea and creatinine in diabetic rats. Elevation of serum lipids in DM represents a risk factor for coronary heart disease [24] . The abnormally high concentration of lipids in serum is mainly due to increase in the mobility of free fatty acids from peripheral depots [25] . It is evident from the literature that many herbal products isolated from plant source serve as good anti-hyperlipidemic agents. For the treatment of various diseases active principles were isolated from natural sources that paved the way for the synthesis of various drugs including metformin [26] . The fruit extract of Momordica charantia was proved to have excellent anti-hyperglycemic and anti-hyperlipidemic activities [27] . In the present study the results show that Mcy protein has significant anti-hyperlipidemic activity by reducing the levels of triglycerides, total cholesterol, LDL cholesterol and VLDL cholesterols in serum as well as in major target tissues. Some of the major anti-hyperlipidemic mechanisms include; 1. Inhibition or reduction of cholesterol biosynthesis especially by lowering the 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG Co A reductase) activity, a key enzyme of cholesterol biosynthesis [28] , 2. reduced triglyceridemic due to decrease in fatty acid synthesis [29] , enhanced catabolism of LDL-C, activation of lecithin-cholesterol acyl transferase and tissue lipases [30] , inhibition of acetyl CoA carboxylase [31] and production of triglyceride precursors such as acetyl CoA and glycerol phosphate. Hyperglycemia and the vascular complications of diabetes correlated with increased non-enzymatic and auto-oxidative glycosylation [6, 7] . While we investigate these mechanisms, one important factor, which contributed for the effect of Mcy protein on lipid metabolism, could be the good glycemic control in diabetic treated rats. Decreased levels of HbA1c and improved glucose tolerance in diabetic group treated with Mcy protein clearly indicate the tight glycemic control in these animals. Mcy protein treatement showed significant anti-hyperlipidemic effect in normalizing serum, hepatic and renal tissue lipids. Mcy protein is equally effective as glybenclamide, however, the antihyperlipidemic effect of Mcy protein in skeletal muscle tissue is very significant and better than glibenclamide indicating additional mechanisms of function.
SGOT and SGPT are hepatic enzymes and biomarkers for abnormal liver funtion or hepatic injury [32] . Elevated SGOT and/or SGPT levels may also be considered as predictors of DM [33] . Administration of Mcy improved the liver function by decreasing the activities of SGPT and SGOT (p<0.05) to normal in diabetic rats. Elevation of SGOT and SGPT will increase the incidence of heart and liver diseases. GOT is found primarily in cells of liver, heart, skeletal muscle, kidney and pancreas. It is released into serum in larger quantities during the tissue damage. Significant rise in serum GOT and GPT activities in diabetic rats could be due to excess protein catabolism with accumulation of aminoacids like glutamate and alanine in the serum of diabetic animals [34] . Mcy protein decreased SGOT activity indicating the protective effect on liver and possibly also on heart as indicated by reduced levels in Mcy treated group. The levels of serum enzymes change in accordance with change in the metabolism in which they are involved. Hence, the improvement in the activities of SGOT and SGPT may be due to improvement in the carbohydrate, fat and protein metabolism on treatment with Mcy protein.
Elevated blood urea and creatinine levels are markers for impaired kidney function in diabetic nephropathy, which were observed in STZ induced diabetic rats [35] . Elevated urea levels in diabetic rats are associated with increased protein breakdown. Positive correlation was seen between hyperglycemia and nephropathy [36] . Treatment of diabetic rats with Mcy reduced the levels of urea and creatinine near to normal. Elevated bilirubin levels indicate enormous destruction of hemoglobin or may be malfunctioning of liver in hemoglobin metabolism [37] . Administration of Mcy normalized the levels of bilirubin. Mcy protein might be eliciting this protective effect directly on the targeted tissues. Another possibility is that it could be due to insulin mimetic activity, pancreatic β cell stimulatory or regenerative function of Mcy protein.
To identify the mechanisms underlying Mcy induced anti-hyperglycemia and antihyperlipedmia, we investigated the effect of Mcy protein on insulin secretion and histology of pancreas. Our studies showed that insulin secretion was significantly elevated in diabetic rats treated with Mcy protein. Cellular Physiology and Biochemistry protein due to possible structural similarity with insulin [10] cannot be ignored. Previously similar studies using protein extracts from the fruits of Momordica charantia showed insulin secretagogue and insulinomimetic activities in STZ induced diabetic rats [38] . Identification of insulin receptor binding-peptide from Momordica charantia [39] signifies the presence of phytohormones that are capable of regulating insulin signaling pathways.
Conclusion
The results indicate that besides lowering the blood glucose levels, Mcy protein has potential beneficial effects by decreasing the levels of total cholesterol, triglycerides, LDLcholesterol, VLDL-cholesterol and increasing HDL-cholesterol. The hepatic function markers SGOT,SGPT activities and serum bilirubin and the renal function markers such as serum creatinine and urea were also normalized after the treatment with Mcy protein compared to untreated diabetic rats. Therefore, our studies suggest that Mcy protein has potent antihyperlipidemic activity besides anti-hyperglycemic activity and shows protective effect against hepatic and renal damage caused in DM. The study also demonstrates that Mcy protein has a regeneration effect and possibly stimulatory effect on the remnant β cells and thus increasing insulin secretion.
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